https://beonemedaffairs.com/global/disease-education/solid-tumors/begenius/rationale-315-final-analysis-perioperative-tislelizumab-in-1l-resectable-nsclc/ 2026-05-14T12:08:53+00:00 https://beonemedaffairs.com/global/wp-content/uploads/sites/2/2026/05/RATIONALE-315_FA_video_v0.2-300x169-1.jpg https://beonemedaffairs.com/global/disease-education/solid-tumors/begenius/rationale-307-tislelizumab-as-1l-treatment-for-advanced-squamous-nsclc/ 2026-05-14T12:47:38+00:00 https://beonemedaffairs.com/global/wp-content/uploads/sites/2/2026/05/RATIONALE-307-Tislelizumab-as-1L-treatment-for-advanced-squamous-NSCLC-300x169-1.png https://beonemedaffairs.com/global/disease-education/solid-tumors/begenius/rationale-315-perioperative-tislelizumab-in-1l-resectable-nsclc/ 2026-05-14T17:34:42+00:00 https://beonemedaffairs.com/global/wp-content/uploads/sites/2/2026/05/RATIONALE-315-Perioperative-tislelizumab-in-1L-resectable-NSCLC-300x169-1.png https://beonemedaffairs.com/global/disease-education/solid-tumors/begenius/what-to-do-in-nsclc-with-low-pd-l1-expression/ 2026-05-18T16:51:18+00:00 https://beonemedaffairs.com/global/wp-content/uploads/sites/2/2026/05/20240705_BeiMedPlus_BeiGeneius_shortvideos_Paz-Ares.jpg https://beonemedaffairs.com/global/disease-education/solid-tumors/begenius/efficacy-of-pd-l1-inhibitors-for-nsclc-in-asian-vs-non-asian-populations/ 2026-05-18T17:49:19+00:00 https://beonemedaffairs.com/global/wp-content/uploads/sites/2/2026/05/efficacy-of-pd-l1-inhibitors-for-nsclc-in-asian-vs-non-asian-populations.jpg https://beonemedaffairs.com/global/disease-education/solid-tumors/begenius/rationale-312-long-term-follow-up-in-es-sclc/ 2026-05-18T18:39:09+00:00 https://beonemedaffairs.com/global/wp-content/uploads/sites/2/2026/05/rationale-312-long-term-follow-up-in-es-sclc.jpg https://beonemedaffairs.com/global/disease-education/hematology/begenius/multidisciplinary-management-of-waldenstroms-macroglobulinemia-providing-specialist-care-beyond-hematology/ 2026-05-19T11:23:20+00:00 https://beonemedaffairs.com/global/wp-content/uploads/sites/2/2026/05/Veronique-Leblond_Joe-Elie-Salem_CardiovascularWM_Preview-scaled.png https://beonemedaffairs.com/global/disease-education/hematology/begenius/relapsed-refractory-waldenstroms-macroglobulinemia-key-considerations-for-managing-pre-treated-patients-2/ 2026-05-19T11:24:52+00:00 https://beonemedaffairs.com/global/wp-content/uploads/sites/2/2026/05/Ramon-Garcia-Sanz_WMPatient_Preview-scaled.png https://beonemedaffairs.com/global/disease-education/hematology/begenius/challenges-in-the-diagnosis-staging-and-clinical-work-up-of-waldenstroms-macroglobulinemia-wm-a-practical-guide-to-current-best-practice-2/ 2026-05-19T11:27:05+00:00 https://beonemedaffairs.com/global/wp-content/uploads/sites/2/2026/05/Alessandra-Tedeschi_DiagnosingWM_Preview-scaled.png https://beonemedaffairs.com/global/disease-education/hematology/begenius/beigeneius-hematology-summit-relapsed-refractory-cll-and-indolent-lymphomas/ 2026-05-20T12:00:06+00:00 https://beonemedaffairs.com/global/wp-content/uploads/sites/2/2026/05/20240705_BeiMedPlus_BeiGeneius_thumbnails-hema_Summit_relapsed_refractory_CLL.jpg https://beonemedaffairs.com/global/disease-education/hematology/begenius/beigeneius-hematology-summit-cll/ 2026-05-26T14:18:10+00:00 https://beonemedaffairs.com/global/wp-content/uploads/sites/2/2026/05/20240705_BeiMedPlus_BeiGeneius_thumbnails-hema_summit_CLL-1.jpg https://beonemedaffairs.com/global/disease-education/solid-tumors/begenius/rationale-307-long-term-os-subgroup-analysis/ 2026-06-08T09:56:15+00:00 https://beonemedaffairs.com/global/wp-content/uploads/sites/2/2026/06/rationale-307-lt-os_th_video_v0-4-png.webp https://beonemedaffairs.com/global/disease-education/solid-tumors/begenius/rationale-303-tislelizumab-in-2l-3l-advanced-nsclc/ 2026-06-29T10:48:48+00:00 https://beonemedaffairs.com/global/wp-content/uploads/sites/2/2026/06/rationale-303_th_video-1-5-no-subtitle.jpg https://beonemedaffairs.com/global/disease-education/hematology/begenius/diagnosis-and-prognosis-in-cll-sll/ 2026-08-03T10:53:34+00:00 https://beonemedaffairs.com/global/wp-content/uploads/sites/2/2026/05/20240705_BeiMedPlus_BeiGeneius_thumbnails-hema_Diagnosis_and_prognosis_in_CLL_SLL.jpg https://beonemedaffairs.com/global/disease-education/hematology/begenius/ash-2023-updates-acquired-mutations-on-btk-inhibitor-containing-therapies/ 2026-08-03T13:21:26+00:00 https://beonemedaffairs.com/global/wp-content/uploads/sites/2/2026/05/ash-2023-updates-acquired-mutations-on-btk-inhibitor-containing-therapies.png https://beonemedaffairs.com/global/disease-education/hematology/begenius/ash-2023-updates-alpine-study-of-zanubrutinib-vs-ibrutinib-in-r-r-cll/ 2026-08-03T13:23:02+00:00 https://beonemedaffairs.com/global/wp-content/uploads/sites/2/2026/05/ash-2023-updates-alpine-study-of-zanubrutinib-vs-ibrutinib-in-rr-cll.png https://beonemedaffairs.com/global/disease-education/hematology/begenius/the-role-of-btk-inhibitors-and-genetic-testing-in-waldenstroms-macroglobulinemia/ 2026-08-03T13:32:03+00:00 https://beonemedaffairs.com/global/wp-content/uploads/sites/2/2026/05/20240705_BeiMedPlus_BeiGeneius_shortvideos_Buske.jpg https://beonemedaffairs.com/global/disease-education/hematology/begenius/ash-2023-updates-rt1-study-of-tislelizumab-plus-zanubrutinib-in-richter-transformation/ 2026-08-03T13:33:40+00:00 https://beonemedaffairs.com/global/wp-content/uploads/sites/2/2026/05/ash-2023-updates-rt1-study-of-tislelizumab-plus-zanubrutinib-in-patients-with-richter-transformation.png https://beonemedaffairs.com/global/disease-education/hematology/begenius/difficult-conversations-in-hematology-discussing-clinical-trial-enrolment-with-a-patient/ 2026-08-03T13:35:46+00:00 https://beonemedaffairs.com/global/wp-content/uploads/sites/2/2026/05/20240705_BeiMedPlus_BeiGeneius_shortvideos_Fallowfield.jpg https://beonemedaffairs.com/global/disease-education/hematology/begenius/beigeneius-hematology-summit-wm/ 2026-08-03T13:36:35+00:00 https://beonemedaffairs.com/global/wp-content/uploads/sites/2/2026/05/begenius-hematology-summit-wm-2022.png https://beonemedaffairs.com/global/disease-education/hematology/begenius/managing-toxicity-with-btk-inhibitors-in-waldenstroms-macroglobulinemia/ 2026-08-03T13:36:49+00:00 https://beonemedaffairs.com/global/wp-content/uploads/sites/2/2026/05/20240705_BeiMedPlus_BeiGeneius_shortvideos_Buske.jpg https://beonemedaffairs.com/global/disease-education/hematology/begenius/ash-2023-updates-btk-inhibitor-monotherapy-for-treatment-naive-cll/ 2026-08-03T13:38:28+00:00 https://beonemedaffairs.com/global/wp-content/uploads/sites/2/2026/05/ash-2023-updates-btk-inhibitor-monotherapy-for-treatment-naive-cll.png https://beonemedaffairs.com/global/disease-education/hematology/begenius/ash-2023-updates-switching-btk-inhibitor-monotherapy/ 2026-08-03T13:39:19+00:00 https://beonemedaffairs.com/global/wp-content/uploads/sites/2/2026/05/ash-2023-updates-switching-btk-inhibitor-monotherapy.png https://beonemedaffairs.com/global/disease-education/hematology/begenius/initiation-of-treatment-for-waldenstroms-macroglobulinemia-practical-guidance-for-starting-treatment-and-managing-complications/ 2026-08-03T13:40:56+00:00 https://beonemedaffairs.com/global/wp-content/uploads/sites/2/2026/05/webinar-2021-initiation-of-treatment-for-waldenstrom-s-macroglobulinemia-scaled.png https://beonemedaffairs.com/global/disease-education/hematology/begenius/relapsed-refractory-waldenstroms-macroglobulinemia-key-considerations-for-managing-pre-treated-patients/ 2026-08-03T13:41:47+00:00 https://beonemedaffairs.com/global/wp-content/uploads/sites/2/2026/05/webinar-2021-relapsed-refractory-waldenstrom-s-macroglobulinemia-key-considerations-for-managing-pre-treated-patients-scaled.png https://beonemedaffairs.com/global/disease-education/hematology/begenius/a-new-era-for-btk-inhibitors-in-the-management-of-b-cell-lymphomas/ 2026-08-03T13:42:00+00:00 https://beonemedaffairs.com/global/wp-content/uploads/sites/2/2026/05/20240705_BeiMedPlus_BeiGeneius_shortvideos_Zinzani.jpg https://beonemedaffairs.com/global/disease-education/hematology/begenius/challenges-in-relapsed-refractory-cll-interactive-case-discussions/ 2026-08-03T13:42:36+00:00 https://beonemedaffairs.com/global/wp-content/uploads/sites/2/2026/05/webinar-2023-challenges-in-relapsed-refractory-cll-interactive-case-discussions-scaled.png https://beonemedaffairs.com/global/disease-education/hematology/begenius/hot-topics-in-the-treatment-of-cll/ 2026-08-03T13:43:15+00:00 https://beonemedaffairs.com/global/wp-content/uploads/sites/2/2026/05/webinar-2024-hot-topics-in-the-treatment-of-cll-scaled.png https://beonemedaffairs.com/global/disease-education/hematology/begenius/difficult-conversations-in-hematology-presenting-treatment-options-for-indolent-lymphomas/ 2026-08-03T13:43:30+00:00 https://beonemedaffairs.com/global/wp-content/uploads/sites/2/2026/05/20240705_BeiMedPlus_BeiGeneius_shortvideos_Fallowfield.jpg https://beonemedaffairs.com/global/disease-education/hematology/begenius/the-present-and-future-of-btk-targeting-in-cll-and-wm-expert-perspectives-from-eric-2024-and-iwwm-12/ 2026-08-03T13:43:55+00:00 https://beonemedaffairs.com/global/wp-content/uploads/sites/2/2026/05/webinar-2024-the-present-and-future-of-btk-targeting-in-cll-and-wm-expert-perspectives-from-eric-2024-and-iwwm-12-scaled.png https://beonemedaffairs.com/global/disease-education/hematology/begenius/challenges-in-the-diagnosis-staging-and-clinical-work-up-of-waldenstroms-macroglobulinemia-wm-a-practical-guide-to-current-best-practice/ 2026-08-03T13:48:32+00:00 https://beonemedaffairs.com/global/wp-content/uploads/sites/2/2026/05/20240705_BeiMedPlus_BeiGeneius_thumbnails-hema_challenges_in_the_diagnosis_staging.jpg https://beonemedaffairs.com/global/disease-education/solid-tumors/begenius/rationale-312-tislelizumab-chemotherapy-in-1l-es-sclc/ 2026-08-03T13:49:35+00:00 https://beonemedaffairs.com/global/wp-content/uploads/sites/2/2026/05/20251029_B1MA_BeGenius_shortvideosPassiglia.jpg https://beonemedaffairs.com/global/disease-education/solid-tumors/begenius/rationale-304-tislelizumab-in-1l-advanced-non-squamous-nsclc/ 2026-08-03T13:49:53+00:00 https://beonemedaffairs.com/global/wp-content/uploads/sites/2/2026/05/BeiGeneius-lung-Talking-head-video-RATIONALE-304-Reck.jpg https://beonemedaffairs.com/global/disease-education/hematology/begenius/begenius-hematology-summit-from-trial-data-to-individual-patients-in-chronic-lymphocytic-leukemia-and-waldenstroms-macroglobulinemia/ 2026-08-03T13:55:30+00:00 https://beonemedaffairs.com/global/wp-content/uploads/sites/2/2026/05/beigeneius_thumbnails-hema_summit_cll-and-wm.png https://beonemedaffairs.com/global/disease-education/hematology/begenius/precision-and-personalization-in-cll-and-b-cell-lymphomas-expert-perspectives-from-iwcll-and-iwnhl/ 2026-08-03T13:58:06+00:00 https://beonemedaffairs.com/global/wp-content/uploads/sites/2/2026/05/webinar-20_thumbnail_1.png https://beonemedaffairs.com/global/disease-education/hematology/begenius/eha-and-beyond-post-congress-season-insights-on-cll-and-wm/ 2026-08-03T13:59:42+00:00 https://beonemedaffairs.com/global/wp-content/uploads/sites/2/2026/05/webinar-19_thumbnail_1.jpg https://beonemedaffairs.com/global/disease-education/hematology/begenius/between-ash-and-eha-updates-trends-new-directions-in-cll-indolent-lymphomas/ 2026-08-03T15:26:26+00:00 https://beonemedaffairs.com/global/wp-content/uploads/sites/2/2026/05/webinar-18_thumbnail_1.png https://beonemedaffairs.com/global/disease-education/hematology/begenius/two-perspectives-one-decision-a-patient-and-physician-discussion-on-shared-decision-making-in-cll/ 2026-11-03T14:02:07+00:00 https://beonemedaffairs.com/global/wp-content/uploads/sites/2/2026/05/webinar-20_thumbnail_1.png https://beonemedaffairs.com/global/disease-education/hematology/begenius/begenius-hematology-summit-2026/ 2026-11-03T14:05:01+00:00 https://beonemedaffairs.com/global/wp-content/uploads/sites/2/2026/08/begenius_p1_update-on-first-line-treatment-strategies-for-cll.jpg